Sanofi's oral TNF inhibitor has been approved for clinical use in China.

On March 1st, the China National Medical Products Administration Drug Evaluation Center (CDE) official website announced that Sanofi's new drug SAR441566 of Class 1 has been approved for clinical trials, with indications for the treatment of moderate to severe rheumatoid arthritis (RA) and moderate to severe plaque psoriasis. Public information shows that SAR441566 is an oral TNF inhibitor. According to Sanofi's public information, SAR441566 is a member of the company's next generation oral drugs and is a TNFR1 signal pathway inhibitor. These drugs can target core pathways related to the disease, and have the convenience of oral administration as well as the effectiveness of antibodies. In a phase 1b clinical trial for treating psoriasis, SAR441566 showed good safety and tolerability while improving symptoms. According to information from the ClinicalTrials platform, SAR441566 is currently in phase 2 clinical trials for the treatment of psoriasis and rheumatoid arthritis.